文档介绍：Cancer Treatment Reviews 37 (2011) 633–642
Contents lists available at ScienceDirect
Cancer Treatment Reviews
journal homepage: rnals/ctrv
Review
Liposome based delivery systems in pancreatic cancer treatment: From bench
to bedside
⇑⇑
Feng Yang a,b, , Chen Jin a,b, Yongjian Jiang a,b,JiLia,b, Yang Di a,b, Quanxing Ni b,c, Deliang Fu a,b,
a Pancreatic Disease Institute, Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China
b Department of Surgery, Shanghai Medical College, Fudan University, Shanghai 200032, China
c Pancreatic Disease Institute, Department of Pancreatic and Hepatobiliary Surgery, Cancer Hospital, Fudan University, Shanghai 200032, China
article info abstract
Article history: Despite rapid advances in cancer diagnosis and treatment, pancreatic cancer remains one of the most dif-
Received 15 October 2010 ficult human malignancies to be treated, with a mortality rate nearly equal to its incidence. Although
Received in revised form 15 January 2011 gemcitabine has been established as the standard first-line treatment for advanced pancreatic cancer,
Accepted 21 January 2011
gemcitabine-bination chemotherapy showed either marginal or no improvement in survival.
Developments in liposomal delivery systems have facilitated the targeting of specific agents for cancer
treatment. Such systems could be developed as